-
Revolution Medicines recently secured FDA clearance for an expanded access program for its investigational pancreatic cancer drug daraxonrasib, following Phase 3 trial data showing a statistically significant overall survival benefit in previously treated metastatic pancreatic ductal adenocarcinoma.
-
This combination of regulatory momentum and unprecedented survival data in a cancer with limited treatment advances has quickly become central to how investors assess the company’s late-stage pipeline.
-
With FDA expanded access in place for daraxonrasib, we’ll now examine how this development reshapes Revolution Medicines’ investment narrative and risks.
Capitalize on the AI infrastructure supercycle with our selection of the 39 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
Revolution Medicines Investment Narrative Recap
To own Revolution Medicines, you need to believe RAS(ON) inhibitors can translate into approved cancer drugs across multiple tumors before the current cash burn becomes a constraint. The FDA’s expanded access clearance for daraxonrasib reinforces the near term focus on the upcoming detailed RASolute 302 data and regulatory filings as the key catalyst, while also heightening the main risk that the whole story still hinges on a few pivotal trials turning into real, durable approvals.
Among recent developments, the US$2.2 billion capital raise stands out in this context. It meaningfully extends the company’s funding runway as operating expenses ramp toward US$1.6 billion to US$1.7 billion in 2026, giving Revolution Medicines more room to advance daraxonrasib through potential filings and to build commercial infrastructure around pancreatic cancer without immediately returning to equity markets if timelines shift or costs run higher than expected.
Yet beneath the excitement around daraxonrasib’s expanded access, investors should also be aware of…
Read the full narrative on Revolution Medicines (it’s free!)
Revolution Medicines’ narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This requires earnings to improve by about $1.3 billion from -$1.1 billion today.
Uncover how Revolution Medicines’ forecasts yield a $133.70 fair value, a 9% downside to its current price.
Exploring Other Perspectives 
RVMD 1-Year Stock Price Chart
Before this news, the most optimistic analysts were already modeling about US$2.1 billion of revenue and US$424.4 million of earnings by 2029, which is far more upbeat than consensus and could look either more justified or too aggressive depending on how the new daraxonrasib data and regulatory steps reshape views of…
Explore 5 other fair value estimates on Revolution Medicines – why the stock might be worth over 2x more than the current price!
The Verdict Is Yours
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
Want Some Alternatives?
Our daily scans reveal stocks with breakout potential. Don’t miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RVMD.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com